Lung cancer vaccine trial continues at UKs Markey Cancer Center
Two University of Kentucky researchers continue their work with a vaccine to prevent lung cancer recurrences in patients following primary treatment of the disease.
Vaccines are being developed with the hope of reducing the unacceptably high rates of recurrence and disease progression seen in the treated lung cancer population. The cancer vaccine program is now enrolling a second cohort of subjects to study the effects of the vaccine in lung cancer patients. The vaccine is delivered following conventional treatment with surgery, radiation therapy or chemotherapy and the patients evaluated for immune responses that could indicate clinical benefit.
Edward A. Hirschowitz, M.D., Associate professor of medicine, and John Yannelli, Ph.D., Associate professor of Microbiology and Immunology, both in the UK College of Medicine, are using white blood cells from the patients blood to make the vaccine. They then administer the vaccine to the patient which allows the patients immune system to recognize and destroy tumor cells that can lead to recurrences after cancer treatment.
"This trial is important in the fight against lung cancer because additional medical therapies are not generally recommended until recurrences are seen," said Hirschowitz. "We are using the window between definitive medical or surgical therapy and lung cancer recurrence to enhance the immune response to a cancer recurrence."
The vaccine in this study uses dendritic cells, the most potent immune inducing cells found in the human body. In the lab these cells can be grown in large numbers then programmed with tumor information that directs the immune system to recognize and kill tumor cells in the body.
"UK is in the forefront of cancer research and therapy with this study," said Yannelli. "Only in the past five years have scientists learned to grow these cells in large numbers and manipulate their biology in laboratory culture. As a result, we can experimentally culture these cells in the lab and inject patients with more of these potent cells to engineer immune responses to different diseases."
In the previous cohort the researchers had very positive biological results and patient outcomes. In this second group, the researchers hope to treat 30 new patients over a period of two years. Each patient receives two injections of the dendritic cells, one month apart. It takes seven days to make the vaccine. Following careful monitoring to insure the vaccine is safe, the antigen loaded dendritic cells are injected into the patient. The second dose is administered a month later.
Initially, the Kentucky Lung Cancer Tobacco Settlement Foundation gave the researchers $200,000 to start the project and an additional; $500,000 was secured from the Cancer Treatment Research Foundation. They have recently secured another grant for $700,000 to further their efforts.
Kentucky has the highest incidence of lung cancer in the country. "Kentucky has such a devastating problem, developing vaccines research here is really important. A seemingly endless stream of lung cancer patients seen in our clinics continually reinforces the importance of this research. " said Hirschowitz "UK is one of the prevailing lung cancer vaccine centers in the U.S."
Louise DuPont | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...